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some point during the course of the disease. Within the latter group, stenosis was 
found to be the diagnosis associated with the highest total costs. ConClusions: 
The treatment pathway for low back pain has not been modelled in such a compre-
hensive manner before. However, the model demands detailed data not currently 
available in most countries. There is a need of further data collection to be able to 
provide more reliable estimates for the burden of spinal disease.
PMS25
The Burden Of IllneSS Of OSTeOPOrOSIS PaTIenTS In The unITed STaTeS 
MedIcare POPulaTIOn
Xie L.1, Wang L.2, Li L.2, Wang Y.1, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
objeCtives: To examine the economic burden and health care utilizations of osteo-
porosis in the U.S. Medicare population. Methods: Osteoporosis patients were 
identified (International Classification of Disease, 9th Revision, Clinical Modification 
[ICD-9-CM] code: 733.0x) from the U.S. national Medicare claims dataset from 
January 1, 2008 through December 31, 2010. The first osteoporosis diagnosis date 
was designated as the index date. One-year continuous enrollment was required 
for all patients pre- and post- index date. Charlson Comorbidity Index (CCI) scores 
and comorbid conditions in the 1-year baseline period were examined. Treatment 
patterns within 60 days post-index date, and health care utilization and costs for the 
follow-up period were analyzed descriptively. Results: A total of 141,833 patients 
(average age 78.1 years) were included in the study sample. Osteoporosis patients 
in the Medicare population were more likely to be female (88.9%), White (88.4%) and 
reside in the Southern U.S. region (38.7%). The average CCI score was 1.80. Comorbid 
conditions were common, including tumor (28.0%), diabetes (25.0%) and chronic 
obstructive pulmonary disease (23.8%). Osteoporosis patients had a high percentage 
of prescriptions for alendronate sodium (12.0%), levothyroxine sodium (10.9%) and 
simvastatin (9.0%) within 60 days post-index date. Health care utilizations analysis 
showed the following results: Medicare carrier (99.4%), Durable Medical Equipment 
(DME, 36.9%), Home Health Agency (HHA, 18.5%), outpatient visits (81.6%) and inpa-
tient hospital (29.6%), Skilled Nursing Facility (SNF, 12.3%) and hospice admissions 
(4.2%) and drug prescription drug claims (part D event) (56.3%). Health care costs 
for osteoporosis patients were determined as follows: Medicare carrier ($4,387), 
DME ($393), HHA ($1,126), outpatient ($10,836), inpatient ($5,728), SNF ($2,363), hos-
pice ($445), pharmacy ($1,736) and total costs ($27,013). ConClusions: Patients 
diagnosed with osteoporosis in the Medicare population have a high percentage 
of carrier and outpatient visits. The current study evidenced that high health care 
utilizations result in considerable expenditures.
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objeCtives: To examine the economic burden and health care utilizations of rheu-
matoid arthritis (RA) patients in the U.S. Medicare population. Methods: The study 
sample was extracted from the national Medicare claims data from 2008 to 2010. 
All patients diagnosed with RA were identified using International Classification of 
Disease, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 714.0x. The 
initial RA diagnosis date was designated as the index date. Comorbid conditions 
during the 12-month pre-index (baseline) period, and treatment patterns within 
60 days post-index date were examined. Health care utilization and costs were 
assessed for each Medicare research identifiable file (RIF) for the 12-month post-
index (follow-up) period. Inflation was adjusted to 2010 U.S. dollars. Results: Out 
of the 21,910 identified patients, 74.5% were male and 81.1% White. RA patients had 
a mean age of 76.8 years, and were more likely to reside in the Southern U.S. region 
(37.7%). The baseline Charlson Comorbidity Index score was 2.27. The most com-
monly diagnosed comorbid conditions included diabetes (34.1%), chronic obstructive 
pulmonary disease (29.3%) and tumor (28.2%). Hydrocodone bitartrate/acetami-
nophen (14.7%), levothyroxine sodium (11.7%) and furosemide (10.7%) were the most 
often prescribed medications for RA patients. Health care utilizations were exam-
ined including proportion of patients with Medicare carrier visits (99.0%), Durable 
Medical Equipment (DME, 47.0%), Home Health Agency (HHA, 25.5%) use, outpatient 
visits (79.5%) and inpatient hospital (36.1%), Skilled Nursing Facility (SNF, 12.7%) and 
hospice admissions (4.4%) and prescription drug (part D event) claims (59.3%). RA 
patients incurred significant Medicare carrier ($5,919), DME ($640), HHA ($1,814), 
outpatient ($13,916), inpatient ($7,977), SNF ($2,389), hospice ($457), prescription 
drug ($2,299) and total costs ($35,412). ConClusions: RA patients were associated 
with more Medicare Carrier service use and outpatient visits, in addition to frequent 
comorbid condition diagnoses, which resulted in higher health care expenditures.
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objeCtives: Assessment of productivity loss caused by RA, CD and psoriasis and 
comparison differences in Poland. Methods: The participants of the M2W study 
were consecutive patients with diagnosed RA, psoriasis and CD, in productive age 
(women 18-60, men 18-65), recruited at regionally stratified sample of 89 outpa-
tient centers (rheumatology, dermatology or gastroenterology). 814 RA, 464 CD and 
822 Ps patients with dominantly low or moderate disease activity were assessed. 
Productivity loss was measured using Work Productivity and Activity Impairment 
(WPAI) questionnaire which included presenteeism, absenteeism and overall work 
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objeCtives: Rheumatoid arthritis (RA) is a chronic autoimmune disease character-
ized by inflammation and destruction of the joints. It is associated with decreased 
quality-of-life in its patients, and pharmacological and non-pharmacological treat-
ments are available. The research aims to estimate the economic burden of RA in 
Taiwan. Methods: The National Health Insurance Research Database (NHIRD), a 
claims-based dataset encompassing 99% of Taiwan’s population, was applied. We 
used a micro-costing approach for direct health care costs and indirect social costs 
by estimating the quantities and prices of cost categories. Direct costs included 
surgeries, hospitalizations, medical devices and materials, lab tests, and drugs. 
The costs and quantities of the direct economic burden were calculated based on 
2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on 
demographic and clinical covariates to calculate the incremental cost related to 
RA. Indirect costs were evaluated by absenteeism and presenteeism, which is the 
decreased productivity of patients. For the indirect burden, we estimated the rate of 
absenteeism and presenteeism from a patient survey and the average salary from 
official statistics. Costs were presented in 2013 USD (1 USD = 29.65 TWD). Results: 
A total of 41,269 RA patients were included in the database with incremental total 
direct cost of $80,303,920 and indirect cost of $105,320,943. This resulted in an aver-
age incremental direct cost of $1,946 per RA patient. Within direct costs, the larg-
est burdens were associated with drugs ($66,794,948; 83.2%), lab tests ($7,563,247; 
9.4%), and hospitalizations ($3,128,309; 3.9%). For indirect costs, absenteeism costs 
and presenteeism costs were $12,975,857 (12.3%) and $92,345,085 (87.7%), respec-
tively. ConClusions: The economic burden of RA in Taiwan is driven by indirect 
health care costs, most notably, presenteeism. Efficient management of RA can 
improve the health status and quality of life, indeed, reduce the economic impact.
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objeCtives: Juvenile idiopathic arthritis (JIA) is the most common rheumatic dis-
ease in children, affecting 1 in 1000. Treatment is shifting to more costly drugs 
and no recent review is available that summarizes all costs for JIA. We aimed to 
summarize all cost-of-illness studies for JIA. Methods: MEDLINE and EMBASE 
were searched from inception to December 2013, using terms for cost-of-illness and 
arthritis. Review articles were also examined. Studies that were not published in 
English were excluded. Data extracted included perspective, data sources, analysis, 
number of subjects, costs and year reported. Purchasing power parities from the 
Organization for Economic Co-operation and Development were used to convert 
costs into United States dollars and the medical component of the US Consumer 
Price Index was used to convert costs to constant US dollars (2012). Data are pre-
sented as cost per person per year. Results: The search yielded 510 unique studies. 
Nine relevant studies were identified with data from 1,340 patients with JIA. Studies 
were conducted in Europe (n= 5), Canada (n= 2), United States (n= 1) and Turkey (n= 1). 
Five studies surveyed patients’ families; 2 used medical records; 2 used both. Six 
studies reported mean direct medical costs; range: $3,304 to $20,613. Six reported 
mean patient/parent time costs; range: $112 to $5,346. Drug costs were $4,665 to 
$14,850 for studies that included newer biologic drugs (n= 2) versus $353 to $1,158 
for those without (n= 2); direct medical costs were $5,140 to $17,633 for those with 
biologic drugs (n= 3) versus $3,304 to $20,613 for those without (n= 4). There was 
inconsistency in how costs were reported. ConClusions: The economic impact 
of JIA is considerable. Newer biologic drugs impact cost-of-illness estimates and 
must be considered when interpreting this information. Current data largely reflects 
European and North American costs. More research will assist policy developers 
and decision makers.
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objeCtives: Low back pain is a common cause for hospital visits and imposes con-
siderable societal costs and loss of quality of life. However, although many patients 
present with symptoms, the vast majority recover after minimal conservative care, 
while a small proportion requires expensive surgical interventions. The objective of 
this model is to create a framework to assess the cost-effectiveness of alternative 
treatments for lumbar spinal diseases and to assess the burden of spinal diseases 
at different stages. Methods: A generic treatment pathway was constructed based 
on a literature review and iterative interaction with an international expert panel 
of orthopaedic specialists. The pathway starts at the point of clinical presentation 
and follows the patient throughout the course of the disease. The model consists 
of a decision tree structure with Markov cohort models at the end of each branch. 
The model follows patients through a range of health care options and outcomes; 
remittances to specialists, surgery, and persistence or resolution of symptoms. 
Death unrelated to back condition is accounted for. The model was populated with 
Swedish data, complemented with other literature and expert opinion. Results: 
An example of the model’s results is the cost distribution over the treatment path-
way. Of the total simulated cost, 85% is associated with patients who do not undergo 
surgery, with the remaining costs attributable to patients who undergo surgery at 
